Results 151 to 160 of about 27,407 (265)

Effectiveness of Telehealth Low‐Carbohydrate Intervention in Preventing Chronic Kidney Disease: A Real‐World, Retrospective, Matched Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Lifestyle interventions targeting metabolic health may influence chronic kidney disease (CKD) risk, particularly among adults with type 2 diabetes and obesity. We evaluated real‐world associations between a telehealth‐delivered, individualized nutrition therapy program (VINT) and CKD incidence and progression compared with usual ...
Shaminie J. Athinarayanan, Petter Bjornstad, Priya V. Shanmugam, Thomas Weimbs, Adam J. Wolfberg, Jeff S. Volek, Jonathan Himmelfarb, Richard J. Johnson   +7 more
wiley   +1 more source

Cardiovascular Autonomic Neuropathy and Indices of Heart Failure in Type 2 Diabetes: The CANCAN Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To quantify the association between cardiovascular autonomic neuropathy (CAN) and heart failure (HF) in individuals with type 2 diabetes (T2D). Materials and Methods Two hundred T2D individuals were recruited from two Danish outpatient clinics between 2021–2024. CAN was defined by abnormal cardiovascular autonomic reflex test results.
Jonas R. Schaarup, Lasse Bjerg, Christian S. Hansen, Daniel R. Witte, Henrik H. Thomsen, Jesper Fleischer, Rodica Pop‐Busui, Signe T. Andersen   +7 more
wiley   +1 more source

SGLT2 Inhibitor-Associated Changes in Urinary Volatile Organic Compounds in Diabetic Kidney Disease: A Comprehensive Study. [PDF]

Nephrology (Carlton)
Hara R, Yamahara H, Hirakawa Y, Hashiba T, Keying H, Tabata H, Nangaku M.   +6 more
europepmc   +1 more source

Relationship Between hsCRP, Glycaemic Control and Response to Sotagliflozin in Type 1 Diabetes: A Post Hoc Analysis of the inTandem3 Trial

Diabetes, Obesity and Metabolism, EarlyView.
Luxcia Kugathasan, Michael J. Davies, Manon Girard, Erik Moedt, Marcel H. A. Muskiet, David Z. I. Cherney   +5 more
wiley   +1 more source

Association of Variability of Monthly Continuous Glucose Monitoring‐Derived Metrics With Diabetic Kidney Disease in Type 1 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background While HbA1c is the standard for monitoring long‐term glycaemic control, it fails to capture glycaemic variability. We investigated the discriminatory capacity of longitudinal continuous glucose monitoring (CGM) metrics and identified CGM metric patterns associated with diabetic kidney disease (DKD) in individuals with type 1 ...
Byeongjae Kang, Rosa Oh, Taeyoung Kim, Jee Hee Yoo, Danbee Kang, Gyuri Kim, Sang‐Man Jin, Myung Jin Chung, Jae Hyeon Kim   +8 more
wiley   +1 more source

Wound healing outcomes in diabetic kidney disease patients receiving SGLT2 inhibitor therapy: a prospective propensity score-matched cohort study. [PDF]

Front Endocrinol (Lausanne)
Zhang RR, Huang S, Wang X, Li X.
europepmc   +1 more source

Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real‐Life Experience From a National Reference Network

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Lipodystrophy syndromes are rare diseases with metabolic and cardiovascular consequences. This study explores the metabolic and renal effects of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with genetic lipodystrophy. Patients and Methods Patients with familial partial lipodystrophy (n = 57) or congenital generalised ...
Léna Robert, Ines Belalem, Corinne Vigouroux, Hippolyte Dupuis, Marie Christine Vantyghem, Mathilde Simonson, Estelle Nobecourt, Héléna Mosbah, Sophie Beliard, Stéphanie Jellimann, Sonja Janmaat, Camille Vatier, Sophie Lamothe   +12 more
wiley   +1 more source

Pharmacist Outreach and SGLT2 Inhibitor Uptake in Patients With Diabetes and Chronic Kidney Disease.

JAMA Netw Open
Pestka DL, Murphy D, Kaplan AN, Taylor BC, Huynh P, Rechtzigel JA, Kjos S, Ellich LM, Atwood M, Polsfuss BA, Thomas AR, Lee JY, Ishani A.   +12 more
europepmc   +1 more source

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A Mendelian Randomization Study. [PDF]

Circ Genom Precis Med
Remala S, Liang L, Shah AM, Buckley LF.
europepmc   +1 more source

Association Between Time in Range and Advanced Cardiovascular‐Kidney‐Metabolic Syndrome in Older Adults With Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiovascular, kidney and metabolic diseases are pathophysiologically interrelated and are conceptualised within the cardiovascular‐kidney‐metabolic (CKM) syndrome framework. However, evidence linking continuous glucose monitoring (CGM) to CKM syndrome remains limited.
Hang Su, Jiaying Ni, Jinghao Cai, Wei Zhu, Yufei Wang, Jian Zhou, Jingyi Lu, Xiaojing Ma   +7 more
wiley   +1 more source